GVH
MCID: GRF003
MIFTS: 72

Graft-Versus-Host Disease (GVH)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 57 37 55 38
Graft Versus Host Disease 38 76 59 55
Graft-Versus-Host Disease, Protection Against 57 38 13
Graft-Versus-Host Disease, Susceptibility to 57 29 40
Graft-Vs-Host Disease 73
Gvhds 57
Gvh 59

Characteristics:

Orphanet epidemiological data:

59
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

OMIM 57 614395
Orphanet 59 ORPHA39812
UMLS via Orphanet 74 C0018133
ICD10 via Orphanet 34 T86.0
KEGG 37 H00084
UMLS 73 C0018133

Summaries for Graft-Versus-Host Disease

OMIM : 57 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395)

MalaCards based summary : Graft-Versus-Host Disease, also known as graft versus host disease, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Graft-versus-host disease and Innate Immune System. The drugs Basiliximab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include Bone, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue... more...

Related Diseases for Graft-Versus-Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 614)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 34.9 IFNG IL10 IL1A TNF
2 acute graft versus host disease 34.2 ARHGAP45 FASLG GZMB IFNG IL10 IL2
3 bronchiolitis obliterans 32.9 GZMB IFNG IL10 IL6 TNF
4 lichen planus 31.1 GZMB IFNG TNF
5 hematopoietic stem cell transplantation 31.1 ARHGAP45 HLA-A HLA-B HLA-C IFNG IL10
6 bronchiolitis 31.0 IFNG IL10 IL6 TNF
7 cutaneous t cell lymphoma 30.9 GZMB IFNG IL2
8 aspergillosis 30.8 IFNG IL10 TNF
9 keratoconjunctivitis 30.7 IFNG IL2 TNF
10 dermatitis, atopic 30.6 IFNG IL10 IL2 TNF
11 exanthem 30.6 IL2 IL6 TNF
12 erythema multiforme 30.5 FASLG GZMB IFNG IL2 TNF
13 pneumonia 30.4 IL10 IL1B IL6 TNF
14 lichen sclerosus 30.4 GZMB HLA-DQB1 HLA-DRB1
15 drug reaction with eosinophilia and systemic symptoms 30.4 HLA-B TNF
16 pure red-cell aplasia 30.4 HLA-A HLA-B HLA-DRB1 IL2
17 hepatitis a 30.3 IFNG IL10 TNF
18 hand, foot and mouth disease 30.3 IFNG IL10 IL6
19 lymphopenia 30.2 FAS FASLG IFNG IL2
20 microscopic polyangiitis 30.2 HLA-B HLA-DRB1 IL10 TNF
21 conjunctivitis 30.2 IFNG IL2 IL6
22 colitis 30.2 IFNG IL10 IL1B IL2 IL6 TNF
23 polyradiculoneuropathy 30.2 HLA-DRB1 IFNG IL10
24 uveitis 30.2 HLA-B IFNG IL10 IL1A TNF
25 myasthenia gravis 30.2 IFNG IL10 IL2 TNF
26 t-cell large granular lymphocyte leukemia 30.1 FASLG GZMB IL2
27 viral hepatitis 30.1 FAS FASLG TNF
28 cytomegalovirus infection 30.1 FAS HLA-A HLA-B IL1B IL6 TNF
29 keratoconjunctivitis sicca 30.1 IL10 IL1A IL1B IL6 TNF
30 herpes zoster 30.1 HLA-A HLA-B IFNG IL10 IL2
31 hemophagocytic lymphohistiocytosis 30.1 FAS GZMB IFNG IL10 TNF
32 extrinsic allergic alveolitis 30.0 IL10 IL1B IL6
33 post-transplant lymphoproliferative disease 30.0 IL10 IL1A IL6 TNF
34 omenn syndrome 30.0 IFNG IL10 TNF
35 aplastic anemia 30.0 FAS FASLG HLA-A HLA-B HLA-DRB1 IFNG
36 anterior uveitis 29.9 HLA-A HLA-B IL6 TNF
37 monocytic leukemia 29.9 IFNG IL1B IL6 TNF
38 gastroenteritis 29.9 IL10 IL1B IL6 TNF
39 influenza 29.9 HLA-B HLA-DQB1 IFNG IL1A
40 lung disease 29.9 IL10 IL1B IL6 TNF
41 pars planitis 29.8 HLA-A HLA-B HLA-DRB1 IL1A
42 pericarditis 29.8 IFNG IL1B IL6 TNF
43 mouth disease 29.7 IFNG IL10 IL1B IL6 TNF
44 synovitis 29.7 IL1B IL6 TNF
45 psoriasis 29.7 HLA-C IFNG IL10 IL1A IL1B IL2
46 myocarditis 29.6 HLA-B HLA-DQB1 IL6 TNF
47 viral infectious disease 29.6 IFNG IL10 IL1B IL2 IL6 TNF
48 skin disease 29.6 HLA-B HLA-C IFNG IL10 IL1A TNF
49 panuveitis 29.5 HLA-A HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
50 multiple sclerosis 29.5 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1B IL2

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease

Symptoms & Phenotypes for Graft-Versus-Host Disease

Clinical features from OMIM:

614395

GenomeRNAi Phenotypes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.47 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.47 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.47 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.47 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.47 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.47 HLA-A HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.47 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.47 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.47 HLA-A HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.47 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.47 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.47 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.47 HLA-A HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.47 HLA-A HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.47 HLA-C
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.89 CD28 FAS GZMB HLA-DQB1 IL10 IL1A
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.89 CD28 FAS GZMB HLA-DQB1 IL10 IL1A

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 CENPF FAS FASLG HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 10.14 CD28 FAS FASLG HLA-DQB1 IFNG IL10
3 digestive/alimentary MP:0005381 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
4 immune system MP:0005387 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.09 CD28 FAS FASLG HLA-DQB1 IFNG IL10
6 integument MP:0010771 9.97 CD28 FAS FASLG IFNG IL10 IL1A
7 liver/biliary system MP:0005370 9.86 FAS FASLG HLA-DQB1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.85 CD28 FAS FASLG IFNG IL10 IL1A
9 respiratory system MP:0005388 9.56 FAS FASLG HLA-DQB1 IFNG IL10 IL2
10 vision/eye MP:0005391 9.23 CD28 FAS FASLG IFNG IL10 IL2

Drugs & Therapeutics for Graft-Versus-Host Disease

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
2
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
4
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
6
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 320-67-2 9444
7
Decitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2353-33-5 451668
8
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
10
Lomustine Approved, Investigational Phase 4,Not Applicable 13010-47-4 3950
11
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
13
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
14
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
15
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
16
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
19
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
20
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
21
Iron Approved Phase 4 7439-89-6 23925
22
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
23
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 171228-49-2 147912
24
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
26
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
29
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
30 Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13909-09-6
31
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
32 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
38 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1556)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
4 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
5 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
6 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
7 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
8 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 Study Evaluating Sirolimus in Kidney Transplant Recipients in India Completed NCT00195481 Phase 4 Rapamune
10 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus Completed NCT00195468 Phase 4 CYCLOSPORINE
11 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
12 Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients Completed NCT00044720 Phase 4 Rapamune
13 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
14 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
15 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
16 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
17 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
18 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
19 ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
20 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
21 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
22 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
23 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
24 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
25 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
26 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
27 The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
28 Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation Withdrawn NCT01071486 Phase 4 Hematological Stem Cell Transplantation
29 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
30 MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
31 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
32 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Unknown status NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
33 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
34 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
35 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
36 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
37 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
38 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
39 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
40 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
41 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
42 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
43 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
44 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
45 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
46 MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Unknown status NCT02240992 Phase 2, Phase 3
47 Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients Unknown status NCT02042690 Phase 3 Chemotherapy
48 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
49 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
50 Allogeneic Transplantation For Severe Osteopetrosis Unknown status NCT00775931 Phase 2, Phase 3 Campath-1H;Cyclophosphamide;Busulfan;Fludarabine monophosphate

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.

Genetic Tests for Graft-Versus-Host Disease

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29 IL10

Anatomical Context for Graft-Versus-Host Disease

MalaCards organs/tissues related to Graft-Versus-Host Disease:

41
T Cells, Bone, Bone Marrow, Myeloid, Skin, Liver, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 3285)
# Title Authors Year
1
Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30344086 )
2019
2
Toxoplasmosis and secondary Guillain-Barré associated with ruxolitinib as graft-versus-host disease treatment. ( 30207078 )
2019
3
Cladribine-related immunosuppression may have fostered graft-versus-host disease after lung transplant for pulmonary Langerhans cell histiocytosis. ( 30270491 )
2019
4
The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease. ( 29410665 )
2018
5
HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature. ( 29721346 )
2018
6
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
7
Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. ( 29330402 )
2018
8
Full-body physical therapy evaluation for pre- and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. ( 29348574 )
2018
9
Topical vitamin D analog for chronic graft versus host disease of the skin. ( 29335622 )
2018
10
Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. ( 29536557 )
2018
11
Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. ( 29705733 )
2018
12
Chronic graft versus host disease presenting as lichen planus pigmentosus. ( 29410549 )
2018
13
A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. ( 29752810 )
2018
14
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. ( 29960041 )
2018
15
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. ( 29643984 )
2018
16
Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. ( 29407317 )
2018
17
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. ( 29740177 )
2018
18
TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and <i>In Silico</i> Search for Small Molecule Binders. ( 29967617 )
2018
19
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
20
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
21
Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. ( 29363541 )
2018
22
TGF-I^-Induced CD8<sup>+</sup>CD103<sup>+</sup>Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. ( 29441062 )
2018
23
Photopheresis of a less than 10-kg child with acute graft versus host disease accompanied with hyperbilirubinemia: A case report. ( 29778715 )
2018
24
Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: InvolvementA ofA Chronic Graft-Versus-Host Disease. ( 29854984 )
2018
25
Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study. ( 29882232 )
2018
26
The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. ( 29763906 )
2018
27
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. ( 29330403 )
2018
28
Total hysterectomy as hematocolpos treatment following bone marrow transplant. A rare complication of chronic graft-versus-host disease. ( 29329824 )
2018
29
Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. ( 29348127 )
2018
30
A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801. ( 29954931 )
2018
31
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
32
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. ( 29720426 )
2018
33
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
34
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
35
Patient-reported outcomes and health status associated with chronic graft-versus-host disease. ( 29858386 )
2018
36
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. ( 29755674 )
2018
37
Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. ( 29664513 )
2018
38
Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. ( 29954253 )
2018
39
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. ( 29707788 )
2018
40
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
41
18F-3'-deoxy-3'-fluorothymidine (FLT) PET imaging for the prediction of acute graft-versus-host disease in mouse hematopoietic stem cell transplant models. ( 29981461 )
2018
42
Correction: Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. ( 29771974 )
2018
43
Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. ( 29359846 )
2018
44
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
45
Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. ( 29959747 )
2018
46
Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. ( 29758393 )
2018
47
Griscelli Syndrome with Fibronodular Sclerodermatous Chronic Graft Versus Host Disease. ( 29398817 )
2018
48
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 29684567 )
2018
49
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
50
Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease. ( 29906586 )
2018

Variations for Graft-Versus-Host Disease

Copy number variations for Graft-Versus-Host Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease

Search GEO for disease gene expression data for Graft-Versus-Host Disease.

Pathways for Graft-Versus-Host Disease

Pathways related to Graft-Versus-Host Disease according to KEGG:

37
# Name Kegg Source Accession
1 Graft-versus-host disease hsa05332

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 ARHGAP45 CD28 FASLG HLA-A HLA-B HLA-C
2
Show member pathways
13.78 CD28 FAS FASLG IFNG IL10 IL1A
3
Show member pathways
13.52 CD28 FAS FASLG IL10 IL1A IL1B
4
Show member pathways
13.42 CD28 FAS FASLG IL10 IL1A IL1B
5
Show member pathways
13.39 FASLG HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1
6
Show member pathways
13.29 HLA-DQB1 HLA-DRB1 IFNG IL1A IL1B IL2
7
Show member pathways
13.18 FAS FASLG HLA-A HLA-B HLA-C IL1B
8
Show member pathways
13.15 FAS FASLG IFNG IL10 IL1B IL2
9
Show member pathways
13.14 FAS FASLG HLA-A HLA-B HLA-C IL2
10
Show member pathways
12.93 CD28 FAS FASLG GZMB HLA-A HLA-B
11 12.89 FAS FASLG IFNG IL2 IL6
12 12.84 FAS FASLG IL1A IL1B TNF
13
Show member pathways
12.81 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10
14
Show member pathways
12.8 FAS FASLG IFNG IL1A IL1B TNF
15
Show member pathways
12.78 IL1A IL1B IL2 IL6 TNF
16
Show member pathways
12.73 IFNG IL10 IL1B IL2 IL6 TNF
17 12.73 CD28 FAS FASLG GZMB IFNG IL10
18
Show member pathways
12.72 CD28 FAS FASLG HLA-A HLA-B HLA-C
19
Show member pathways
12.71 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
20
Show member pathways
12.7 FAS FASLG IL1A IL1B TNF
21
Show member pathways
12.65 FAS FASLG GZMB HLA-A HLA-B HLA-C
22
Show member pathways
12.6 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10
23
Show member pathways
12.57 CD28 FAS IFNG IL10 IL1A IL1B
24 12.55 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
25
Show member pathways
12.46 IFNG IL1B IL2 IL6 TNF
26
Show member pathways
12.45 CD28 HLA-DQB1 HLA-DRB1 IL2
27
Show member pathways
12.43 IFNG IL1A IL1B IL6 TNF
28
Show member pathways
12.42 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1A
29 12.41 FAS HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1
30
Show member pathways
12.4 IFNG IL1B IL6 TNF
31
Show member pathways
12.39 FAS FASLG GZMB IL1A TNF
32
Show member pathways
12.39 FAS FASLG IFNG IL1A IL1B TNF
33
Show member pathways
12.39 HLA-A HLA-B HLA-C IFNG IL10 IL1A
34
Show member pathways
12.37 FAS FASLG IFNG IL1B IL6 TNF
35
Show member pathways
12.35 IL10 IL1B IL2 IL6 TNF
36 12.33 FAS FASLG GZMB TNF
37 12.33 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
38 12.32 IL10 IL1A IL1B IL6 TNF
39
Show member pathways
12.31 IL1A IL1B IL6 TNF
40 12.31 HLA-A HLA-B HLA-C IL1A IL6
41 12.31 CD28 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1
42 12.31 HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNG IL10 IL1A
43
Show member pathways
12.3 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
44
Show member pathways
12.25 CD28 IFNG IL10 IL1B IL2 IL6
45
Show member pathways
12.21 IFNG IL10 IL1A IL1B IL2 IL6
46 12.21 IFNG IL1A IL1B IL2 IL6 TNF
47 12.2 IFNG IL1A IL1B TNF
48 12.2 CD28 IFNG IL10 IL2 IL6 TNF
49 12.18 FASLG IL10 IL1A IL1B IL6 TNF
50
Show member pathways
12.17 FASLG GZMB HLA-A HLA-DRB1 IFNG IL1B

GO Terms for Graft-Versus-Host Disease

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.91 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
2 cell surface GO:0009986 9.81 CD28 FAS FASLG HLA-A HLA-B HLA-C
3 trans-Golgi network membrane GO:0032588 9.71 HLA-DPB1 HLA-DQB1 HLA-DRB1
4 recycling endosome membrane GO:0055038 9.7 HLA-A HLA-B HLA-C
5 phagocytic vesicle membrane GO:0030670 9.67 HLA-A HLA-B HLA-C
6 endocytic vesicle membrane GO:0030666 9.65 HLA-DPB1 HLA-DQB1 HLA-DRB1
7 transport vesicle membrane GO:0030658 9.63 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 clathrin-coated endocytic vesicle membrane GO:0030669 9.58 HLA-DPB1 HLA-DQB1 HLA-DRB1
9 MHC class II protein complex GO:0042613 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
10 MHC class I protein complex GO:0042612 9.43 HLA-A HLA-B HLA-C
11 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
13 extracellular space GO:0005615 10.11 FASLG IFNG IL10 IL1A IL1B IL2
14 extracellular region GO:0005576 10.07 ARHGAP45 FAS FASLG IFNG IL10 IL1A

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.99 IL10 IL1B IL6 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.99 FAS IFNG IL1B IL2 TNF
3 T cell receptor signaling pathway GO:0050852 9.96 CD28 HLA-DPB1 HLA-DQB1 HLA-DRB1
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL6 TNF
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.91 HLA-DPB1 HLA-DQB1 HLA-DRB1
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.91 FAS FASLG TNF
7 cytokine-mediated signaling pathway GO:0019221 9.91 FASLG IL10 IL1A IL1B IL2 IL6
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IFNG IL2 IL6
9 regulation of insulin secretion GO:0050796 9.9 IFNG IL1B TNF
10 type I interferon signaling pathway GO:0060337 9.89 HLA-A HLA-B HLA-C
11 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TNF
12 response to glucocorticoid GO:0051384 9.88 IL10 IL1B IL6 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IFNG IL1B TNF
14 apoptotic signaling pathway GO:0097190 9.86 CD28 FAS FASLG TNF
15 regulation of signaling receptor activity GO:0010469 9.86 FASLG IFNG IL10 IL1A IL1B IL2
16 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.85 IL1A IL1B TNF
17 humoral immune response GO:0006959 9.84 CD28 IFNG IL6 TNF
18 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.83 IL1A IL1B IL2
19 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.83 HLA-A HLA-B HLA-C
20 positive regulation of cytokine secretion GO:0050715 9.82 IL10 IL1A TNF
21 positive regulation of mitotic nuclear division GO:0045840 9.82 CD28 IL1A IL1B
22 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.81 HLA-A HLA-B HLA-C
23 extrinsic apoptotic signaling pathway GO:0097191 9.81 FAS FASLG IFNG TNF
24 negative regulation of neurogenesis GO:0050768 9.8 IL1B IL6 TNF
25 positive regulation of T cell mediated cytotoxicity GO:0001916 9.8 HLA-A HLA-B HLA-C
26 positive regulation of interferon-gamma production GO:0032729 9.8 HLA-DPB1 IL1B IL2 TNF
27 positive regulation of glial cell proliferation GO:0060252 9.79 IL1B IL6 TNF
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.78 IFNG IL1B TNF
29 regulation of regulatory T cell differentiation GO:0045589 9.77 CD28 IFNG IL2
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 IL10 IL1B TNF
31 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.74 HLA-DPB1 HLA-DQB1 HLA-DRB1
32 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL2 IL6
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 CD28 IL2
34 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
35 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
36 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
37 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.72 CD28 IL1A IL1B
38 positive regulation of T cell proliferation GO:0042102 9.72 CD28 HLA-DPB1 IL1B IL2 IL6
39 ectopic germ cell programmed cell death GO:0035234 9.71 IL1A IL1B
40 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 IL10 TNF
42 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.7 HLA-DQB1 HLA-DRB1
43 positive regulation of fever generation GO:0031622 9.7 IL1B TNF
44 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.7 HLA-A HLA-B HLA-C
45 protection from natural killer cell mediated cytotoxicity GO:0042270 9.69 HLA-A HLA-B
46 chronic inflammatory response to antigenic stimulus GO:0002439 9.68 IL1B TNF
47 sequestering of triglyceride GO:0030730 9.68 IL1B TNF
48 fever generation GO:0001660 9.67 IL1A IL1B
49 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.67 HLA-DQB1 HLA-DRB1
50 receptor biosynthetic process GO:0032800 9.67 IL10 TNF

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 FASLG IFNG IL10 IL1A IL1B IL2
2 interleukin-1 receptor binding GO:0005149 9.32 IL1A IL1B
3 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
4 peptide antigen binding GO:0042605 9.1 HLA-A HLA-B HLA-C HLA-DPB1 HLA-DQB1 HLA-DRB1
5 protein binding GO:0005515 10.16 ARHGAP45 CD28 CENPF FAS FASLG GZMB

Sources for Graft-Versus-Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....